诊断学理论与实践

诊断学理论与实践 >

2021 , Vol. 20 >Issue 06: 592 - 595

DOI: https://doi.org/10.16150/j.1671-2870.2021.06.016

综述

尘螨在特应性皮炎中的致病机制及相关免疫治疗应用研究进展

展开
  • 上海交通大学医学院附属新华医院皮肤科,上海 200092

收稿日期: 2021-02-10

  网络出版日期: 2021-12-25

收起

本文引用格式

罗雅方, 徐倩玥, 余红 . 尘螨在特应性皮炎中的致病机制及相关免疫治疗应用研究进展[J]. 诊断学理论与实践, 2021 , 20(06) : 592 -595 . DOI: 10.16150/j.1671-2870.2021.06.016

参考文献

[1] Weidinger S, Novak N. Atopic dermatitis[J]. Lancet, 2016, 387(10023):1109-1122.
[2] Meng Q, Liu X, Li P, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis[J]. Int Forum Allergy Rhinol, 2016, 6(8):862-870.
[3] 龙玲珑, 姚煦, 杨雪源. 变应原特异性免疫治疗特应性皮炎的进展[J]. 国际皮肤性病学杂志, 2017, 43(2):65-68.
[4] Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies[J]. Allergol Int, 2017, 66(3):398-403.
[5] Takemura M, Nakahara T, Hashimoto-Hachiya A, et al. Glyteer, Soybean Tar, Impairs IL-4/Stat6 Signaling in Murine Bone Marrow-Derived Dendritic Cells: The Basis of Its Therapeutic Effect on Atopic Dermatitis[J]. Int J Mol Sci, 2018, 19(4):1169.
[6] Guttman-Yassky E, Nograles KE, Krueger JG. Contras-ting pathogenesis of atopic dermatitis and psoriasis--part Ⅱ: immune cell subsets and therapeutic concepts[J]. J Allergy Clin Immunol, 2011, 127(6):1420-1432.
[7] Jaitley S, Saraswathi T. Pathophysiology of langerhans cells[J]. J Oral Maxillofac Pathol, 2012, 16(2):239-244.
[8] 周杰, 陈曙光, 宋志强. 特异性免疫疗法治疗特应性皮炎[J]. 中华临床免疫和变态反应杂志, 2021, 15(1):76-81.
[9] Huang FL, Liao EC, Yu SJ. House dust mite allergy: Its innate immune response and immunotherapy[J]. Immunobiology, 2018, 223(3):300-302.
[10] 宋志强. 特应性皮炎的变应原特异性免疫治疗[J]. 中国医学文摘(皮肤科学), 2016, 33(2):180-183.
[11] Yu SJ, Liao EC, Tsai JJ. Effects of local nasal immunotherapy in allergic airway inflammation: using urea denatured Dermatophagoides pteronyssinus[J]. Hum Vaccin Immunother, 2015, 11(4):915-921.
[12] Fuiano N, Incorvaia C. Dissecting the causes of atopic dermatitis in children: less foods, more mites[J]. Allergol Int, 2012, 61(2):231-243.
[13] Bumbacea RS, Corcea SL, Ali S, et al. Mite allergy and atopic dermatitis: Is there a clear link?(Review)[J]. Exp Ther Med, 2020, 20(4):3554-3560.
[14] Kato T, Takai T, Fujimura T, et al. Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes[J]. Allergy, 2009, 64(9):1366-1374.
[15] Serhan N, Basso L, Sibilano R, et al. House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation[J]. Nat Immunol, 2019, 20(11):1435-1443.
[16] Miller JD. The Role of Dust Mites in Allergy[J]. Clin Rev Allergy Immunol, 2019, 57(3):312-329.
[17] 黄迎, 钱秋芳, 张志红, 等. 1140例特应性皮炎患儿血清过敏原检测及分析[J]. 中国麻风皮肤病杂志, 2019, 35(11):689-691,700.
[18] Kim J, Lee S, Woo SY, et al. The indoor level of house dust mite allergen is associated with severity of atopic dermatitis in children[J]. J Korean Med Sci, 2013, 28(1):74-79.
[19] Cid BJ, Perez-Mateluna G, Iturriaga C, et al. Is there an association between indoor allergens and the severity of atopic dermatitis?[J]. Int J Dermatol, 2019, 58(4):433-439.
[20] Wisniewski JA, Agrawal R, Minnicozzi S, et al. Sensitization to food and inhalant allergens in relation to age and wheeze among children with atopic dermatitis[J]. Clin Exp Allergy, 2013, 43(10):1160-1170.
[21] Su KW, Chiu CY, Tsai MH, et al. Asymptomatic toddlers with house dust mite sensitization at risk of asthma and abnormal lung functions at age 7 years[J]. World Allergy Organ J, 2019, 12(9):100056.
[22] Posa D, Perna S, Resch Y, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life[J]. J Allergy Clin Immunol, 2017, 139(2):541-549.
[23] Bremmer SF, Simpson EL. Dust mite avoidance for the primary prevention of atopic dermatitis: A systematic review and meta-analysis[J]. Pediatr Allergy Immunol, 2015, 26(7):646-654.
[24] Bumbacea RS, Corcea SL, Ali S, et al. Mite allergy and atopic dermatitis: Is there a clear link?(Review)[J]. Exp Ther Med, 2020, 20(4):3554-3560.
[25] Kanchongkittiphon W, Gaffin JM, Phipatanakul W. Child with atopic dermatitis[J]. Ann Allergy Asthma Immunol, 2015, 114(1):6-11.
[26] 宋志强, 郝飞. 特异性免疫治疗在特应性皮炎中的应用[J]. 中华临床免疫和变态反应杂志, 2008, 2(2):137-141.
[27] Zhong H, Deng X, Song Z, et al. Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite[J]. J Eur Acad Dermatol Venereol, 2015, 29(7):1318-1324.
[28] Zhou J, Chen S, Song Z. Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis[J]. Allergy Asthma Proc, 2021, 42(2):e47-e54.
[29] Qin YE, Mao JR, Sang YC, et al. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis[J]. Int J Dermatol, 2014, 53(5):650-655.
[30] Liu L, Chen J, Xu J, et al. Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1):3540-3547.
[31] 彭戈, 韩秀萍. 特异性免疫治疗在特应性皮炎中的研究进展[J]. 临床皮肤科杂志, 2017, 46(8):69-71.
[32] Fujita H, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy[J]. Clin Transl Allergy, 2012, 2(1):2.
[33] Nahm DH, Kim ME, Kwon B, et al. Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis[J]. Yonsei Med J, 2016, 57(6):1420-1426.
[34] Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis[J]. J Allergy Clin Immunol, 2012, 130(4):925-931.
[35] Elazab SZ, Hessam WF, Gomaa AH. Effect of Cluster Allergen-Specific Immunotherapy in Patients with Atopic Dermatitis Sensitive to House Dust Mite[J]. Egypt J Immunol, 2018, 25(2):97-106.
[36] Choi JS, Ryu HR, Yoon CH, et al. Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy[J]. Ann Dermatol, 2015, 27(1):82-86.
[37] Di Rienzo V, Cadario G, Grieco T, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study[J]. Ann Allergy Asthma Immunol, 2014, 113(6):671-673.
[38] You HS, Yang MY, Kim GW, et al. Effectiveness of specific sublingual immunotherapy in korean patients with atopic dermatitis[J]. Ann Dermatol, 2017, 29(1):1-5.
[39] Lee J, Lee H, Noh S, et al. Retrospective Analysis on the Effects of House Dust Mite Specific Immunotherapy for More Than 3 Years in Atopic Dermatitis[J]. Yonsei Med J, 2016, 57(2):393-398.
[40] Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials[J]. J Allergy Clin Immunol, 2013, 132(1):110-117.
[41] Tam H, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema[J]. Cochrane Database Syst Rev, 2016, 2:CD008774.
Options
文章导航

/

〈 〉